

Biologics and Biosimilars-EMEA Market Status and Trend Report 2015-2026

<https://marketpublishers.com/r/B80B7931074EN.html>

Date: September 2020

Pages: 141

Price: US\$ 3,480.00 (Single User License)

ID: B80B7931074EN

Abstracts

Report Summary

Biologics and Biosimilars-EMEA Market Status and Trend Report 2015-2026 offers a comprehensive analysis on Biologics and Biosimilars industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Biologics and Biosimilars 2015-2019, and development forecast 2020-2026

Main market players of Biologics and Biosimilars in EMEA, with company and product introduction, position in the Biologics and Biosimilars market

Market status and development trend of Biologics and Biosimilars by types and applications

Cost and profit status of Biologics and Biosimilars, and marketing status

Market growth drivers and challenges Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Biologics and Biosimilars market in 2020. COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing

panic among the population, and uncertainty about future. This report also analyses the impact of Coronavirus COVID-19 on the Biologics and Biosimilars industry.

The report segments the EMEA Biologics and Biosimilars market as:

EMEA Biologics and Biosimilars Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2015-2026):

Europe

Middle East

Africa

EMEA Biologics and Biosimilars Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2015-2026):

Monoclonal Antibodies

Interferon

Erythropoietin

Insulin

Vaccines

Others

EMEA Biologics and Biosimilars Market: Application Segment Analysis (Consumption Volume and Market Share 2015-2026; Downstream Customers and Market Analysis)

Tumor

Diabetes

Cardiovascular

Hemophilia

Others

EMEA Biologics and Biosimilars Market: Players Segment Analysis (Company and Product introduction, Biologics and Biosimilars Sales Volume, Revenue, Price and Gross Margin):

Roche

Eli Lilly

Sanofi-Aventis

Amgen

Novo Nordisk

AbbVie

Merck

Pfizer

Johnson & Johnson
Novartis
Gelgen
Ganlee
3sbio
Innovent
Biotech
Changchun High Tech
Dong Bao
CP Guojian

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF BIOLOGICS AND BIOSIMILARS

- 1.1 Definition of Biologics and Biosimilars in This Report
- 1.2 Commercial Types of Biologics and Biosimilars
 - 1.2.1 Monoclonal Antibodies
 - 1.2.2 Interferon
 - 1.2.3 Erythropoietin
 - 1.2.4 Insulin
 - 1.2.5 Vaccines
 - 1.2.6 Others
- 1.3 Downstream Application of Biologics and Biosimilars
 - 1.3.1 Tumor
 - 1.3.2 Diabetes
 - 1.3.3 Cardiovascular
 - 1.3.4 Hemophilia
 - 1.3.5 Others
- 1.4 Development History of Biologics and Biosimilars
- 1.5 Market Status and Trend of Biologics and Biosimilars 2015-2026
 - 1.5.1 EMEA Biologics and Biosimilars Market Status and Trend 2015-2026
 - 1.5.2 Regional Biologics and Biosimilars Market Status and Trend 2015-2026

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Biologics and Biosimilars in EMEA 2015-2019
- 2.2 Consumption Market of Biologics and Biosimilars in EMEA by Regions
 - 2.2.1 Consumption Volume of Biologics and Biosimilars in EMEA by Regions
 - 2.2.2 Revenue of Biologics and Biosimilars in EMEA by Regions
- 2.3 Market Analysis of Biologics and Biosimilars in EMEA by Regions
 - 2.3.1 Market Analysis of Biologics and Biosimilars in Europe 2015-2019
 - 2.3.2 Market Analysis of Biologics and Biosimilars in Middle East 2015-2019
 - 2.3.3 Market Analysis of Biologics and Biosimilars in Africa 2015-2019
- 2.4 Market Development Forecast of Biologics and Biosimilars in EMEA 2020-2026
 - 2.4.1 Market Development Forecast of Biologics and Biosimilars in EMEA 2020-2026
 - 2.4.2 Market Development Forecast of Biologics and Biosimilars by Regions 2020-2026

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole EMEA Market Status by Types

3.1.1 Consumption Volume of Biologics and Biosimilars in EMEA by Types

3.1.2 Revenue of Biologics and Biosimilars in EMEA by Types

3.2 EMEA Market Status by Types in Major Countries

3.2.1 Market Status by Types in Europe

3.2.2 Market Status by Types in Middle East

3.2.3 Market Status by Types in Africa

3.3 Market Forecast of Biologics and Biosimilars in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Biologics and Biosimilars in EMEA by Downstream Industry

4.2 Demand Volume of Biologics and Biosimilars by Downstream Industry in Major Countries

4.2.1 Demand Volume of Biologics and Biosimilars by Downstream Industry in Europe

4.2.2 Demand Volume of Biologics and Biosimilars by Downstream Industry in Middle East

4.2.3 Demand Volume of Biologics and Biosimilars by Downstream Industry in Africa

4.3 Market Forecast of Biologics and Biosimilars in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BIOLOGICS AND BIOSIMILARS

5.1 EMEA Economy Situation and Trend Overview

5.2 Biologics and Biosimilars Downstream Industry Situation and Trend Overview

CHAPTER 6 BIOLOGICS AND BIOSIMILARS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

6.1 Sales Volume of Biologics and Biosimilars in EMEA by Major Players

6.2 Revenue of Biologics and Biosimilars in EMEA by Major Players

6.3 Basic Information of Biologics and Biosimilars by Major Players

6.3.1 Headquarters Location and Established Time of Biologics and Biosimilars Major Players

6.3.2 Employees and Revenue Level of Biologics and Biosimilars Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

- 6.4.2 Investment or Disinvestment News
- 6.4.3 New Product Development and Launch

CHAPTER 7 BIOLOGICS AND BIOSIMILARS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Roche

- 7.1.1 Company profile
- 7.1.2 Representative Biologics and Biosimilars Product
- 7.1.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Roche

7.2 Eli Lilly

- 7.2.1 Company profile
- 7.2.2 Representative Biologics and Biosimilars Product
- 7.2.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Eli Lilly

7.3 Sanofi-Aventis

- 7.3.1 Company profile
- 7.3.2 Representative Biologics and Biosimilars Product
- 7.3.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Sanofi-Aventis

7.4 Amgen

- 7.4.1 Company profile
- 7.4.2 Representative Biologics and Biosimilars Product
- 7.4.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Amgen

7.5 Novo Nordisk

- 7.5.1 Company profile
- 7.5.2 Representative Biologics and Biosimilars Product
- 7.5.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Novo Nordisk

7.6 AbbVie

- 7.6.1 Company profile
- 7.6.2 Representative Biologics and Biosimilars Product
- 7.6.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of AbbVie

7.7 Merck

- 7.7.1 Company profile
- 7.7.2 Representative Biologics and Biosimilars Product
- 7.7.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Merck

7.8 Pfizer

- 7.8.1 Company profile
- 7.8.2 Representative Biologics and Biosimilars Product

- 7.8.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Pfizer
- 7.9 Johnson & Johnson
 - 7.9.1 Company profile
 - 7.9.2 Representative Biologics and Biosimilars Product
 - 7.9.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 7.10 Novartis
 - 7.10.1 Company profile
 - 7.10.2 Representative Biologics and Biosimilars Product
 - 7.10.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Novartis
- 7.11 Gelgen
 - 7.11.1 Company profile
 - 7.11.2 Representative Biologics and Biosimilars Product
 - 7.11.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Gelgen
- 7.12 Ganlee
 - 7.12.1 Company profile
 - 7.12.2 Representative Biologics and Biosimilars Product
 - 7.12.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Ganlee
- 7.13 3sbio
 - 7.13.1 Company profile
 - 7.13.2 Representative Biologics and Biosimilars Product
 - 7.13.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of 3sbio
- 7.14 Innovent
 - 7.14.1 Company profile
 - 7.14.2 Representative Biologics and Biosimilars Product
 - 7.14.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Innovent
- 7.15 Biotech
 - 7.15.1 Company profile
 - 7.15.2 Representative Biologics and Biosimilars Product
 - 7.15.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Biotech
- 7.16 Changchun High Tech
- 7.17 Dong Bao
- 7.18 CP Guojian

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOLOGICS AND BIOSIMILARS

- 8.1 Industry Chain of Biologics and Biosimilars
- 8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BIOLOGICS AND BIOSIMILARS

9.1 Cost Structure Analysis of Biologics and Biosimilars

9.2 Raw Materials Cost Analysis of Biologics and Biosimilars

9.3 Labor Cost Analysis of Biologics and Biosimilars

9.4 Manufacturing Expenses Analysis of Biologics and Biosimilars

CHAPTER 10 MARKETING STATUS ANALYSIS OF BIOLOGICS AND BIOSIMILARS

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Biologics and Biosimilars-EMEA Market Status and Trend Report 2015-2026

Product link: <https://marketpublishers.com/r/B80B7931074EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B80B7931074EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970